Labor & Human Resources
At a markup scheduled for Aug. 1, committee will look at Chairman Kennedy's (D-Mass.) S 2649, a bill designed to encourage development of drug abuse treatments by offering such therapies seven years of market exclusivity in a provision modeled on the Orphan Drug Act ("The Pink Sheet" June 4, T&G-3). The bill would require HHS to look at advertising and marketing of legal drugs in the context of determining if a correlation exists between consumption of legal and illegal drugs.
You may also be interested in...
Zydus Cadila is to begin testing a three-dose recombinant DNA vaccine candidate in Phase III Indian trials, which might enter late-stage development ahead of Inovio and AnGes. The company promised to provide 100-150 million doses by end of 2021 at the J.P. Morgan Conference, though adherence could be a roadblock.
Sun Pharma’s founder and MD shares with Scrip his views on some key big picture issues, including leveraging pandemic-related regulatory experience for urgently needed products, expectations in the US market, the outlook for M&A, and the potential of e-pharmacies in India.
India is allowing importers and manufacturers of certain devices – for whom new licensing requirements came into effect on 1 January – to continue marketing their products for six months if they have already applied for a license. See what Rajiv Nath from the Association of Indian Medical Device Industry (AiMeD) said about it here.